MX382284B - Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes. - Google Patents

Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes.

Info

Publication number
MX382284B
MX382284B MX2016014210A MX2016014210A MX382284B MX 382284 B MX382284 B MX 382284B MX 2016014210 A MX2016014210 A MX 2016014210A MX 2016014210 A MX2016014210 A MX 2016014210A MX 382284 B MX382284 B MX 382284B
Authority
MX
Mexico
Prior art keywords
antibody
fcrn
autoimmune diseases
treatment
receptor
Prior art date
Application number
MX2016014210A
Other languages
English (en)
Spanish (es)
Other versions
MX2016014210A (es
Inventor
Dongok Shin
Eun Sun Kim
Hae- Young YONG
Hyea Kyung Ahn
Jae Kap Jeong
Min Sun Kim
Seung Kook Park
Sung Wuk Kim
Tae Hyoung Yoo
Yeon Jung Song
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Publication of MX2016014210A publication Critical patent/MX2016014210A/es
Publication of MX382284B publication Critical patent/MX382284B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rehabilitation Therapy (AREA)
MX2016014210A 2014-04-30 2015-04-30 Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes. MX382284B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (2)

Publication Number Publication Date
MX2016014210A MX2016014210A (es) 2017-05-01
MX382284B true MX382284B (es) 2025-03-13

Family

ID=54358928

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016014210A MX382284B (es) 2014-04-30 2015-04-30 Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes.
MX2021005193A MX2021005193A (es) 2014-04-30 2016-10-28 Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021005193A MX2021005193A (es) 2014-04-30 2016-10-28 Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.

Country Status (21)

Country Link
US (6) US10544226B2 (enExample)
EP (2) EP3137504B1 (enExample)
JP (1) JP6449441B2 (enExample)
KR (2) KR101954906B1 (enExample)
CN (2) CN106459215B (enExample)
AU (2) AU2015253915B2 (enExample)
CA (2) CA3095295C (enExample)
DK (1) DK3137504T5 (enExample)
EA (1) EA038470B1 (enExample)
ES (1) ES2952583T3 (enExample)
FI (1) FI3137504T3 (enExample)
HU (1) HUE062403T2 (enExample)
IL (2) IL248159B (enExample)
MX (2) MX382284B (enExample)
NZ (2) NZ737666A (enExample)
PL (1) PL3137504T3 (enExample)
PT (1) PT3137504T (enExample)
RS (1) RS64542B1 (enExample)
SA (1) SA516380194B1 (enExample)
SG (1) SG11201608208VA (enExample)
WO (1) WO2015167293A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
KR20190015704A (ko) * 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
HRP20240048T1 (hr) * 2016-07-29 2024-03-29 Momenta Pharmaceuticals, Inc. Fcrn antitijela i postupci njihove uporabe
EP3533451B1 (en) 2017-01-21 2022-07-27 Guangzhou Hanfang Pharmaceuticals Co., Ltd. Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
WO2018229249A1 (en) * 2017-06-15 2018-12-20 Ucb Biopharma Sprl Method for the treatment of immune thrombocytopenia
US11773168B2 (en) 2017-12-13 2023-10-03 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
AU2019361247B2 (en) 2018-10-16 2025-06-26 UCB Biopharma SRL Method for the treatment of Myasthenia Gravis
BR112021008778A2 (pt) * 2018-11-06 2021-08-31 Immunovant Sciences Gmbh Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
CA3157797A1 (en) * 2019-11-19 2021-05-27 Christine Morel COQUERY Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
WO2021160116A1 (zh) * 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
AU2021299606A1 (en) * 2020-06-29 2023-02-23 Hanall Biopharma Co., Ltd. Formulation for anti-FcRN antibody
EP4192864A4 (en) * 2020-08-06 2024-09-04 Stelexis Therapeutics, LLC IL-8 ANTIBODIES AND METHODS OF USE THEREOF
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
EP4384548A4 (en) * 2021-08-13 2024-11-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND THEIR USES
WO2023091920A1 (en) * 2021-11-16 2023-05-25 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
TW202409085A (zh) 2022-05-30 2024-03-01 南韓商韓兀生物製藥股份有限公司 具有改善之安定性的抗ＦｃＲｎ抗體或其抗原結合片段
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CN120077065A (zh) * 2022-07-27 2025-05-30 阿布林克斯有限公司 与新生儿Fc受体的特定表位结合的多肽
CA3266954A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh METHODS OF TREATMENT OF GRAVES DISEASE USING ANTI-FCRN ANTIBODIES
CA3266951A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh METHODS OF TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ANTI-FCRN ANTIBODIES
WO2024184444A1 (en) 2023-03-08 2024-09-12 Immunovant Sciences Gmbh High concentration protein formulations with polysorbate excipients and methods of making the same
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
WO2025093717A1 (en) * 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005013912A2 (en) * 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
CA2606378A1 (en) 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
EP2336329B8 (en) 2007-06-01 2012-11-21 Omt, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
EP2966089B1 (en) * 2011-06-02 2020-03-25 Dyax Corp. Fc receptor binding proteins
KR20130071961A (ko) * 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
HUE062403T2 (hu) 2023-10-28
IL280613A (en) 2021-03-25
EP3137504A4 (en) 2018-02-28
US20200109201A1 (en) 2020-04-09
US10544226B2 (en) 2020-01-28
SG11201608208VA (en) 2016-11-29
ES2952583T3 (es) 2023-11-02
RS64542B1 (sr) 2023-09-29
DK3137504T3 (da) 2023-08-14
CN111138540B (zh) 2023-07-25
WO2015167293A1 (en) 2015-11-05
US20250026835A1 (en) 2025-01-23
JP2017522043A (ja) 2017-08-10
IL248159B (en) 2021-02-28
IL280613B (en) 2021-12-01
CN111138540A (zh) 2020-05-12
DK3137504T5 (en) 2024-10-14
CN106459215B (zh) 2019-12-24
KR20160145779A (ko) 2016-12-20
KR101954906B1 (ko) 2019-03-08
KR20180093128A (ko) 2018-08-20
MX2016014210A (es) 2017-05-01
IL248159A0 (en) 2016-11-30
CA2945086C (en) 2020-12-29
MX2021005193A (es) 2021-09-08
US20190135917A1 (en) 2019-05-09
AU2015253915B2 (en) 2018-05-10
CA2945086A1 (en) 2015-11-05
SA516380194B1 (ar) 2020-10-14
US11613578B2 (en) 2023-03-28
CA3095295C (en) 2023-01-10
AU2015253915A1 (en) 2016-12-01
EA201692192A1 (ru) 2017-04-28
JP6449441B2 (ja) 2019-01-09
CA3095295A1 (en) 2015-11-05
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
US20240092913A1 (en) 2024-03-21
CN106459215A (zh) 2017-02-22
US20170210801A1 (en) 2017-07-27
NZ737666A (en) 2018-10-26
AU2018203582A1 (en) 2018-06-14
US20230235063A1 (en) 2023-07-27
PL3137504T3 (pl) 2023-10-16
EP3137504A1 (en) 2017-03-08
EP4241852A2 (en) 2023-09-13
FI3137504T3 (fi) 2023-08-07
EP3137504B1 (en) 2023-05-10
EP4241852A3 (en) 2023-11-15
EA038470B1 (ru) 2021-09-01
AU2018203582B2 (en) 2019-05-02
BR112016025319A2 (pt) 2017-12-12
NZ726089A (en) 2017-12-22

Similar Documents

Publication Publication Date Title
MX382284B (es) Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes.
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
MX2025007735A (es) Anticuerpos anti-il36r
PE20180499A1 (es) Anticuerpos de union a tau
CO2018000809A2 (es) Anticuerpos para cd40
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
JO3568B1 (ar) عوامل ربط cd123 واستخداماتها
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PH12016501366A1 (en) Novel anti-baff antibodies
GT201300149A (es) Proteinas de union al tnf-a
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
EA202091569A1 (ru) Моноклональные антитела и способы их применения
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
AR117735A1 (es) ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2016012620A (es) Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6